The latest quarterly R&D expense is $102.56 Million with a QoQ Growth of +5.11%. Research and Development (R&D) expenses represent the costs incurred by a company in developing new products, services, or processes.
Q2 FY2027 (2026-08-01).
Reported quarterly R&D expense; no daily interpolation. Q2 FY2027 (2026-08-01): $102.56M.
$102.56M
$102.56 Million
Q2 FY2027 · 2026-08-01
+5.11%
vs. $97.57M prior quarter
23
Quarters of data available
| Period | R&D Expense | QoQ Growth | YoY Growth |
|---|---|---|---|
| Q2 FY2027Period end 2026-08-01 | $102.56M | +5.11% | +19.79% |
| Q1 FY2027Period end 2026-05-02 | $97.57M | +8.99% | +17.21% |
| Q4 FY2026Period end 2026-01-31 | $89.52M | +3.82% | +22.16% |
| Q3 FY2026Period end 2025-11-01 | $86.22M | +0.71% | +11.99% |
| Q2 FY2026Period end 2025-08-02 | $85.61M | +2.85% | +11.95% |
| Q1 FY2026Period end 2025-05-03 | $83.24M | +13.60% | +14.07% |
| Q4 FY2025Period end 2025-01-31 | $73.28M | -4.82% | -0.20% |
| Q3 FY2025Period end 2024-11-02 | $76.99M | +0.67% | +26.59% |
| Q2 FY2025Period end 2024-08-03 | $76.48M | +4.80% | +19.55% |
| Q1 FY2025Period end 2024-05-04 | $72.97M | -0.62% | +20.88% |
| Q4 FY2024Period end 2024-01-31 | $73.43M | +20.73% | +34.47% |
| Q3 FY2024Period end 2023-10-28 | $60.82M | -4.92% | +21.71% |
| Q2 FY2024Period end 2023-07-29 | $63.97M | +5.97% | +52.86% |
| Q1 FY2024Period end 2023-04-29 | $60.37M | +10.55% | +47.29% |
| Q4 FY2023Period end 2023-01-31 | $54.60M | +9.27% | -56.82% |
| Q3 FY2023Period end 2022-10-29 | $49.97M | +19.41% | +68.32% |
| Q2 FY2023Period end 2022-07-30 | $41.85M | +2.10% | +64.42% |
| Q1 FY2023Period end 2022-04-30 | $40.98M | -67.59% | +74.18% |
| Q4 FY2022Period end 2022-01-31 | $126.46M | +325.97% | +526.65% |
| Q3 FY2022Period end 2021-10-31 | $29.69M | +16.64% | N/A |
| Q2 FY2022Period end 2021-07-31 | $25.45M | +8.16% | N/A |
| Q1 FY2022Period end 2021-04-30 | $23.53M | +16.60% | N/A |
| Q4 FY2021Period end 2021-01-31 | $20.18M | N/A | N/A |
Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.
